Advanced glycation end products and diabetic retinopathy

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)


Diabetic retinopathy (DR) has a complex pathogenesis which is impacted by a raft of systemic abnormalities and tissue-specific alterations occurring in response to the diabetes milieu. Many pathogenic processes play key roles in retinal damage in diabetic patients. One such pathway is the formation and accumulation of advanced glycation endproducts (AGEs) and advanced lipoxidation end products (ALEs) which are relevant modifications with roles in the initiation and progression of pathology. In this review, AGE/ALE formation in the diabetic retina is discussed alongside their impact on retinal cell function. In addition, various inhibitors of the AGE-RAGE system and their therapeutic utility for DR will also be evaluated.

Original languageEnglish
Pages (from-to)3234-40
JournalCurrent medicinal chemistry
Issue number26
Publication statusPublished - 2013


  • Animals
  • Diabetic Retinopathy
  • Glycosylation
  • Glycosylation End Products, Advanced
  • Humans


Dive into the research topics of 'Advanced glycation end products and diabetic retinopathy'. Together they form a unique fingerprint.

Cite this